Zobrazeno 1 - 10
of 1 805
pro vyhledávání: ''
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Tahani Atieh, Shebli Atrash, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Susana Hajjar, Zahra Mahmoudjafari, Julie Quick, Anne Wishna, Justin Riffel, Joseph McGuirk, Ghulam Rehman Mohyuddin, Al-Ola Abdallah
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:912-919
Triple-class relapsed/refractory multiple myeloma (RRMM) has a poor prognosis. This study analyzed the clinical outcomes of Belantamab mafadotin in combination with dexamethasone (Bd) in triple-class RRMM.We identified 35 patients with triple-class R
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:835-840
Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult patients wit
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e938-e946
One key clinical challenge remains in how to sequence treatments in follicular lymphoma (FL). The chemoimmunotherapy rituximab cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone (R-CHOP) has been a standard treatment option for two
Autor:
Lalit Kumar, Mohammad Mir Hussain, Rajegowda Chethan, Ranjit Kumar Sahoo, Prabhat S. Malik, Om Dutt Sharma, Anisha Mathew, Ankit Jha, Ritu Gupta, Atul Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Soumyaranjan Malik, Ashish Dutt
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e826-e835
Autologous stem cell transplant (ASCT) is a standard therapy for transplant eligible patients of multiple myeloma (MM). To evaluate impact of time to transplant on subsequent outcomes, we analyzed data on consecutive MM patients who received novel ag
Autor:
Marlise Luskin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:436-441
Acute lymphoblastic leukemia (ALL) is an aggressive blood cancer that affects both children and adults. Although the majority of children diagnosed with ALL are now cured and outcomes are improving for younger adults, older adults diagnosed with ALL
Autor:
Jessika Contreras, Amar Srivastava, Pamela Samson, Todd DeWees, Ramaswamy Govindan, Maria Q. Baggstrom, Daniel Morgensztern, Michael Roach, Shahed N. Badiyan, Jeffrey Bradley, Saiama Waqar, Clifford Robinson
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 113:742-748
Our purpose was to evaluate the maximum tolerated dose of hypofractionated proton beam radiation therapy with concurrent weekly carboplatin/paclitaxel in patients with stage II-III non-small cell lung cancer.A phase I trial was designed using the tim
Autor:
Demetris Papamichael, Guilherme S. Lopes, Curt L. Olswold, Jean-Yves Douillard, Richard A. Adams, Timothy S. Maughan, Eric Van Cutsem, Alan P. Venook, Heinz-Josef Lenz, Volker Heinemann, Richard Kaplan, Carsten Bokemeyer, Benoist Chibaudel, Axel Grothey, Takayuki Yoshino, John Zalcberg, Aimery De Gramont, Qian Shi
Publikováno v:
European Journal of Cancer. 163:1-15
Colorectal cancer (CRC) affects many older adults. We investigated the efficacy and safety of adding anti-epidermal growth factor receptor (EGFR) agents to doublet chemotherapy (DC) in older patients.Patients with RAS wild-type (WT) metastatic CRC (m
Autor:
Alexis B. Cortot, Didier Debieuvre, L. Moreau, Radj Gervais, Jacques Margery, Julien Mazieres, Olivier Molinier, Michel Poudenx, Alexandra Langlais, Nicolas Girard, Patrick Dumont, Gérard Zalcman, Franck Morin, Virginie Westeel, Pierre-Jean Souquet, Eric Pichon, Fabrice Barlesi, Maurice Pérol, Jérôme Dauba, Jacques Cadranel, Clarisse Audigier-Valette, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 164:84-90
Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditi
Autor:
Sebastian F. Schoppmann, Emmanuella Guenova, Gerd Jomrich, Matthias Preusser, Robin Ristl, Dariga Ramazanova, Aysegül Ilhan-Mutlu, Richard Grose, Christina Fassnacht, Dagmar Kollmann, Yi-Chien Tsai
Publikováno v:
European Journal of Surgical Oncology. 48:383-390
The effects of cytotoxic chemotherapy on the expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) in cancer cells and peritumoral cells are unclear. The aim of this study was to investigate the impact of neoadjuvant chemotherapy on PD-